Breaking Finance News

Innophos Holdings, Inc. (NASDAQ:IPHS) has been downgraded to Hold in a report by Zacks Investment Research today.

Zacks Investment Research has downgraded Innophos Holdings, Inc. (NASDAQ:IPHS) to Hold in a report released on 10/12/2016.

Yesterday Innophos Holdings, Inc. (NASDAQ:IPHS) traded 0.41% higher at $39.35. The company’s 50-day moving average is $39.64 and its 200-day moving average is $39.03. The last closing price is up 0.81% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 82,238 shares of the stock traded hands, down from an average trading volume of 106,823

Performance Chart

Innophos Holdings, Inc. (NASDAQ:IPHS)

With a total market value of $0, Innophos Holdings, Inc. has price-earnings ratio of 30.18 with a one year low of $22.06 and a one year high of $44.42 .

Brief Synopsis About Innophos Holdings, Inc. (NASDAQ:IPHS)

Innophos Holdings, Inc. is a producer of nutritional specialty ingredients with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. The Company also provides bioactive mineral and nutritional ingredients. Its segments include Specialty Phosphates US & Canada, Specialty Phosphates Mexico, and GTSP & Other. The Specialty Phosphates US & Canada segment and Specialty Phosphates Mexico segment comprises product lines, such as Specialty Ingredients; Food and Technical Grade Purified Phosphoric Acid (PPA), and Technical Grade Sodium Tripolyphosphate (STPP) & Detergent Grade PPA. The GTSP & Other segment includes fertilizer co-product Granular Triple Super Phosphate (GTSP) and other non-specialty phosphate products. It produces a range of botanical, enzyme and mineral-based ingredients through various production processes, including spray drying, roller compactions, grinding, wet granulations, solvent extractions and custom blending.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.